内部人交易雷达

数据截至 2026年11月5日 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Aspen Neuroscience, Inc.

ASPE · — · CIK 0002124080 · Healthcare · Biotechnology

内部人信号

86.0 / 100

4 位买方 · 6 条买入交易行 · $68.0M 买入总额

为什么有这个信号？

买方广度较强
买入规模较强
角色中等
近期性较强
确信度较强
评分构成

每条进度条是这一部分在总分里的分数，五项相加就是总分。

买入人数+28.0 / 35
买入金额+24.5 / 25
Buyers' roles+14.0 / 20
多近+9.5 / 10
买入与卖出+10.0 / 10

哪些因素限制了当前分数？

  • ⚠ Buyers' roles add little · most senior buyer: TenPercentOwner（CEO、董事长和持股 10% 以上的股东得分最低）
  • ✓ 买入人数多 · 至少 4 位内部人
  • ✓ 买入很近 · 最近一次在 2026-11-02

日均成交量在页面其他位置作为市场背景列出，不计入评分。

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道按交易日绘制；菱形标记较晚的公开披露日，在此之前市场并不知道该交易。卖出仅作背景。

MayJunJulAugSepOctNov
ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERTTenPercentOwner
○●
ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCDirector,TenPercentOwner
○◇●◇
Thompson Peter A.Director,TenPercentOwner
○◇●◇
ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL LTenPercentOwner
●
Hasnain FaheemExecutive Chair
○
Spaventa AndrewDirector
○
● 买入▼ 卖出○ 其他◇ 公开披露

—

买方广度与集中度

合资格买方4
买入集中度29%最大买方： ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · $20.0M
聚集买入 · 15天4 insiders峰值活动： 2026-11-02–2026-11-02

Roles in the peak window: Director,TenPercentOwner, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

86.0 / 100

最新留档分数

↑ +14.1 pts相对上一个留档快照
  1. 71.9
  2. 86.0

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

6买入
0卖出
21其他 Form 4 交易行
6SEC 申报 · 365天
买入6 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他21 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M
—
3M
—
6M
—
12M
—

波动率与流动性

波动率
—
Beta
—
平均每日成交额
USD 10.9M

估值

市值
USD 371.0M
P/E
—

基本面

利润率
0.0%
ROE
—
细分行业
Biotechnology

市场数据

价格数据截至：2026-11-05 · 价格来源：OpenBB/yfinance · 来自 Yahoo Finance：市值, 利润率 · Status: PASS

空头余额

FINRA 报告中没有该股票代码的空头余额。

FINRA 结算日：2026-10-15 · 获取日期 2026-11-03 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

交易日期披露日期Reporting owner类型证券股数平均价格估算金额来源
2026-11-022026-11-04Thompson Peter A.买入 (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC 申报 ↗
2026-11-022026-11-04ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC买入 (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC 申报 ↗
2026-11-022026-11-02ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL L买入 (P)Common Stock1,200,000USD 15.00USD 18,000,000SEC 申报 ↗
2026-11-022026-11-02ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT买入 (P)Common Stock1,333,333USD 15.00USD 19,999,995SEC 申报 ↗

Form 4 申报证据

27 transaction lines in the latest 365-day window; 27 in local history.

交易日期披露日期申报人类型证券股数平均价格估算金额来源
2026-11-022026-11-04Thompson Peter A.买入 (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC 申报 ↗
2026-11-022026-11-04Thompson Peter A.C (C)Common Stock2,589,132USD —USD —SEC 申报 ↗
2026-11-022026-11-04ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC买入 (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC 申报 ↗
展开近期 Form 4 证据 (9 grouped rows)
交易日期披露日期申报人类型证券股数平均价格估算金额来源
2026-11-022026-11-04Thompson Peter A.买入 (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC 申报 ↗
2026-11-022026-11-04Thompson Peter A.C (C)Common Stock2,589,132USD —USD —SEC 申报 ↗
2026-11-022026-11-04ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC买入 (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC 申报 ↗
2026-11-022026-11-04ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCC (C)Common Stock2,589,132USD —USD —SEC 申报 ↗
2026-11-022026-11-02Spaventa AndrewC (C)Common Stock250,415USD —USD —SEC 申报 ↗
2026-11-022026-11-02Hasnain FaheemC (C)Common Stock36,349USD —USD —SEC 申报 ↗
2026-11-022026-11-02ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL L买入 (P)Common Stock1,200,000USD 15.00USD 18,000,000SEC 申报 ↗
2026-11-022026-11-02ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT买入 (P)Common Stock1,333,333USD 15.00USD 19,999,995SEC 申报 ↗
2026-11-022026-11-02ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERTC (C)Common Stock1,541,537USD —USD —SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-11-05
排名版本US-v1.2
数据质量REVIEW MAPPING_REVIEW · mapping-review-required
股票代码ASPE
CIK0002124080
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
交易所—

数据覆盖

本地 Form 4 历史27 transaction lines from 2026-11-02 to 2026-11-02
6 P purchase lines · 0 S sale lines · 21 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-11-05. Mapping status is an audit field and does not erase SEC filing evidence.